Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study

Jiaye Liua,b,c, Lifeng Wangb,c, Yuying Houra,b*, Yan Zhaoa, Zhihui Doua, Ye Ma, Dawei Zhanga, Yasong Wuba, Decai Zhaoa, Zhongfu Liu, Fujie Zhanga, Lei Jina, Ji-Yuan Zhanga,b,c, Ruonan Xub, Ming Shib, Lei Huangb, Zunyou Wua, Mengjie Hanb, George F. Gaoa and Fu-Sheng Wanga,b,c

*Contributed equally to this work.

Abstract

Using normalization of CD4 counts as the main evaluation parameter of complete immune restoration for HIV-1 patients under antiretroviral therapy (ART) might not be enough. A comprehensive evaluation system more accurately reflecting immune restoration are urgently needed. Totally, 91,805 HIV-1 patients from 17 tertiary hospitals in China during 2005–2018 were included in this study. Immune restoration and mortality were assessed. Patients initiated ART with baseline CD4 counts <50, 50–199, 200–349, 350–499, and ≥500 cells/µL, and results showed an increase in the median CD4 counts to 445 (12-year), 467 (12-year), 581 (11-year), 644 (7-year), and 768 cells/µL (5-year), as well as the CD4/CD8 ratio to 0.59 (12-year), 0.65 (12-year), 0.79 (11-year), 0.82 (7-year), and 0.9 (5-year), respectively. The median CD8 count was relatively high (median range 732–845 cells/µL), regardless of the baseline CD4 counts. Furthermore, the probabilities of death in patients achieving CD4 counts ≥500 cells/µL and CD4/CD8 ratio ≥0.8 simultaneously were significantly lower than those in patients achieving either CD4 counts ≥500 cells/µL (2.77% vs 3.50%, p=0.02) or CD4/CD8 ≥0.8 (2.77% vs 4.28%, p<0.001) after 12-year of ART. In this study, a new binary-indicator would accurately assess immune restoration in the era of “treat all.”

Article history

Received 18 August 2020; Revised 5 October 2020; Accepted 13 October 2020

Keywords HIV; CD4; CD8; CD4/CD8 ratio; Immune restoration

Introduction

It is well known that HIV-1 infection mainly attacks CD4 cells and induces progressive loss of CD4 counts [1]. Alteration in CD4 counts during the treatment of HIV-1 infection is significantly associated with immune restoration, morbidity, and mortality [2–4]. Although patients are more likely to achieve normalized CD4 counts through early initiation of ART, overactivation and expansion of CD8 T cells, as well as systemic inflammation are observed in such patients. Furthermore, a few studies have reported that there is an U-shaped relationship between CD8 counts and all-cause mortality [5], and a low CD4/CD8 ratio is associated with increased AIDS- or non-AIDS-related morbidity and mortality in patients on ART after adjusting the CD4 count [6,7]. The CD4 counts, CD8 counts, and CD4/CD8 ratio are considered to reflect immune status and predict different outcomes. In the era of “treat all”, restoration of CD4 cell counts (≥500 cells/µL) alone, which was previously accepted as a satisfactory treatment outcome indicator, may not be sufficient for clinical practices. Hence, it is necessary to establish a comprehensive immune assessment system integrating additional immune parameters.

Based on data from previous large-scale prospective studies and recommendations from the World Health Organization (WHO), there are four CD4 cut-off values to start ART for people living with HIV-1 (PLWH) in China [8]. Since 2002, PLWHs with CD4 counts <200 cells/µL have been eligible for free ART. From 2008 to 2013, this criterion was modified to <350 cells/µL, and then to <500 cells/µL until 2015. Since 2016, all PLWHs are eligible for free ART, regardless of the CD4 count. So far, based on China’s National Free Antiretroviral Treatment Program (NFATP) database,
a series of analyses have been performed to explore the efficacy of ART in adult PLWH in China [9–12]. These studies indicated that the scale-up of ART and earlier initiation of therapy had significantly reduced the mortality rate among those patients. However, they mainly analyzed participants who received free ART before 2012 and had low CD4 counts at ART initiation, mortality as the main outcome, and an evaluation period of under 5 years. Hence, a comprehensive evaluation of immune restoration and assessment of >10-year disease outcomes in national patients who received free ART in China are still lacking.

To address the above-mentioned issues, this real-world observational study aimed to: (1) analyze the dynamics of CD4 counts, CD8 counts, and CD4/CD8 ratio during long-term ART; (2) investigate the cumulative probability of immune restoration and mortality and identify their associated factors, and (3) explore a comprehensive evaluation system for immune restoration.

Methods

Study design and patients

This real-world cohort study was based on existing records in the NFATP database, including data on HIV-1-infected patients who received free ART with long-term follow-up care in China [13,14]. We included the patients if they were older than 15 years of age, treatment-naive, and started ART between Jan 1, 2005 and Jun 30, 2018. The locations of the 17 hospitals are presented in Appendix 1. The following patients were excluded from this study: (1) patients from Taiwan province, Hong Kong and Macau Special Administration Regions, and other foreign countries, (2) patients without ART initiation regimen, or baseline CD4 counts, or baseline CD8 counts, and (3) patients without any follow-up records. Finally, we established two cohort sets: death analysis set and immune analysis set (Figure 1). Baseline information and follow-up records, including demographic, clinical characteristics, and laboratory test data were collected from local healthcare workers using standardized case report forms. This study was approved by our Research Ethics Committee, and written informed consent was obtained from each patient.

Procedure

We assessed two main outcomes: immune restoration and death. Follow-up data were included up to Dec 31, 2018. Patients were considered lost to follow-up if they missed follow-up ≥90 days. For each participant, the longest observation duration was 12 years from the date of ART initiation.

Immune restoration was indicated by CD4 counts ≥200, ≥350, and ≥500 cells/µL, CD4/CD8 ratio ≥0.4 and ≥0.8, or simultaneous achievement of CD4 counts ≥500 cells/µL and CD4/CD8 ratio ≥0.8 among patients with different baseline CD4 counts. The observation period was from the date of ART initiation to the date of occurrence of outcomes. Patients were censored at death, loss to follow-up, transfer to other facilities, or the last follow-up visit before Dec 31, 2018.

We also assessed the survival rate by measuring the time from the initiation of ART to death (all-cause) or censoring. Patients were censored at loss to follow-up, transfer to other facilities, or the last follow-up visit.

![Figure 1. Enrollment of HIV-1-infected patients initiated on ART between Jan 1, 2005 and Jun 30, 2018.](image-url)
**Statistical analysis**

We conducted three analyses. First, we assessed the dynamics of CD4 counts, CD8 counts, CD4/CD8 ratio at baseline and different time points after ART initiation stratified by the baseline CD4 counts: <50, 50–199, 200–349, 350–499, and ≥500 cells/µL. Second, we assessed the probability of CD4 cell counts recovery, CD4/CD8 ratio restoration, and binary-indicator immune restoration (CD4 counts ≥500 cells/µL and CD4/CD8 ratio ≥0.8), and explored the factors associated with achieving these events. We estimated these probabilities using Kaplan-Meier analysis stratified by the baseline CD4 counts, and determined statistical significance using the log-rank test for running parallel hazard rates and a two-stage procedure for crossing hazard rates [15]. Third, we assessed the probability of death using Kaplan-Meier analysis and explored factors associated with death using the Cox proportional model. The detail of three analyses was described in Appendix 2.

All significance tests performed were two-sided. P values less than 0.05 were deemed statistically significant and 95% confidence interval (CI) was calculated for point estimates. All analyses were carried out using SAS software version 9.4 (SAS Institute) or SPSS version 23.0.

**Results**

**Baseline characteristics of PLWH**

Baseline characteristics of two analyses sets among the 91,805 enrolled cases are summarized in Table 1. In mortality analysis, the mean age of PLWH was 36.91 years and 74,719 (81.39%) patients were male. In immune analysis, the mean age of PLWH was 36.49 years and 66,889 (81.52%) patients were male. The median baseline CD4 counts, CD8 counts, and CD4/CD8 ratio were similar between immune and mortality analysis. Baseline CD4 counts <200 cells/µL were observed in 45.49% of patients in mortality analysis and 44.21% in immune analysis (Table 1). In China, plasma HIV RNA monitoring is free for each patient at least once per year. In the NFATP database, there were 64,083 patients on ART who had better viral load records during the follow-up period, and 61,379 of them (95.78%) were found to achieve full viral suppression (HIV-1 RNA <400 copies/mL) [16].

**The dynamics of CD4 counts, CD8 counts, CD4/CD8 ratio in PLWH on ART**

The mean CD4 counts in healthy Chinese individuals ranges between 720–820 cells/µL [17–19]. Here, ART was shown to effectively restore CD4 counts in PLWH with different baseline CD4 counts, especially within the first 6 months of ART initiation (Figure 2(A) and Figure 3(A–C)). After 5 years of ART, the median CD4 counts reached 333 (237–453), 400 (296–519), 533 (417–662), 632 (513–778), and 768 cells/µL (605–947) in the five groups with baseline CD4 counts <50, 50–199, 200–349, 350–499, and ≥500 cells/µL, respectively. The corresponding values persistently increased to 433 (312–586), 472 (353–619), and 572 cells/µL (441–743) in patients with baseline CD4 counts <50, 50–199, and 200–349 cells/µL, respectively, at 10 years after ART initiation. However, after a 12-year follow-up period, the median CD4 count did not reach 500 cells/µL in patients with baseline CD4 counts <200 cells/µL.

Healthy Chinese subjects usually have mean CD8 counts of 520–590 cells/µL [17–19]. In this study, in patients with baseline CD4 counts <50 cells/µL, the

### Table 1. Baseline features of HIV-1-infected patients.

| Characteristics | Death Analysis Set | Immune Analysis Set |
|-----------------|--------------------|---------------------|
| Overall, n      | 91805              | 82053               |
| Sex, male       | 74,719 (81.39)     | 66,889 (81.52)      |
| Age at Start ART (year), mean ± SD | 36.91 ± 12.61 | 36.49 ± 12.28 |
| Route of HIV infection |                |                    |
| Median (IQR) |                                      |
| <50              | 20,623 (22.46)     | 17,493 (21.32)      |
| 50–199           | 23,698 (25.81)     | 21,119 (25.74)      |
| 200–349          | 28,794 (31.36)     | 26,481 (32.27)      |
| ≥350–499         | 14,141 (15.40)     | 12,937 (15.77)      |
| ≥500             | 7103 (7.74)        | 6358 (7.75)         |
| Baseline CD4 (cells/µL) |                |                    |
| Median (IQR) |                                      |
| <50              | 819 (531–1188)     | 832 (545–1200)      |
| 50–199           | 23,698 (25.81)     | 21,119 (25.74)      |
| 200–349          | 28,794 (31.36)     | 26,481 (32.27)      |
| ≥350–499         | 14,141 (15.40)     | 12,937 (15.77)      |
| ≥500             | 7103 (7.74)        | 6358 (7.75)         |
| Baseline CD8 (cells/µL) |                |                    |
| Median (IQR) |                                      |
| <50              | 20,623 (22.46)     | 17,493 (21.32)      |
| 50–199           | 23,698 (25.81)     | 21,119 (25.74)      |
| 200–349          | 28,794 (31.36)     | 26,481 (32.27)      |
| ≥350–499         | 14,141 (15.40)     | 12,937 (15.77)      |
| ≥500             | 7103 (7.74)        | 6358 (7.75)         |
| Initial antiretroviral regimen |                |                    |
| AZT+3TC + NVP/EFV | 18,196 (19.82)     | 16,787 (20.46)      |
| D4T+3TC + NVP/EFV | 8949 (9.75)        | 7852 (9.57)         |
| TDF-STC+LPVr     | 53,740 (58.54)     | 48,401 (58.99)      |
| TDF+3TC + LPVr   | 2696 (2.94)        | 2215 (2.70)         |
| Other            | 8224 (8.96)        | 6798 (8.28)         |
| Calendar year at baseline |                |                    |
| 2005–2006        | 3164 (3.45)        | 2609 (3.18)         |
| 2007–2013        | 28,794 (31.46)     | 26,447 (32.23)      |
| 2014–2015        | 25,056 (27.29)     | 23,347 (28.45)      |
| 2016–2018        | 34,699 (37.80)     | 29,650 (36.14)      |

Notes: Data are expressed as n (%) or median (IQR). ART: antiretroviral therapy; SD: standard deviation; IQR: interquartile range; HIV: human immunodeficiency virus; MSM: men who have sex with men; Hb: hemoglobin; TDF: tenofovir disoproxil fumarate; STC: lamivudine; D4T: stavudine; EFV: efavirenz; NVP: nevirapine; AZT: zidovudine; LPVr: lopinavir/ritonavir.
Figure 2. The dynamic trajectories of CD4 counts, CD8 counts, CD4/CD8 ratio in HIV-1 patients based on five groups of baseline CD4 counts over a 12 years follow-up period. Although the CD4 counts were quickly restored to above 500 cells/µL after ART in patients with baseline CD4 counts ≥350 cells/µL, in advanced HIV-1 patients (CD4 counts <200 or <50 cells/µL), the restoration of CD4 counts was slower and more difficult to reach 500 cells/µL even after 12 years of ART (A). HIV-1-infected patients on ART usually displayed high levels of CD8 counts (B), and rarely showed restoration of normal CD4/CD8 ratio(C) during the 12-year follow-up among patients with different baseline CD4 counts. The pink shaded areas in A and B represent a range of mean CD4 and CD8 counts in Chinese healthy population from different researches, respectively. Dash symbol in “Number at risk” means that when the numbers of patients were less than 200 in the corresponding follow-up points, we will not exhibit the trajectories. IQR = inter quartile range.
median CD8 count rapidly increased to 849 cells/µL (580–1192) within the first 6 months of ART initiation, gradually reaching a peak of 980 cells/µL (698–1342) after a 2-year follow-up period, and then slowly decreased and stabilized at around 800 cells/µL. However, in patients with baseline CD4 counts of 50–199 cells/µL, the CD8 counts slightly increased from 720 to 810 cells/µL after ART and then maintained steady levels. All ART patients with baseline CD4 counts of 200–349, 350–499, and ≥500 cells/µL showed a significantly decreasing trajectory within the first year of ART, and then stabilized at around 750–850 cells/µL at 2 or 3 years after ART. In general, CD8 counts remained higher in all patients than in healthy controls regardless of the baseline CD4 counts (Figure 2(B)).

The mean CD4/CD8 ratio among healthy people has been reported to be around 1.5 [17–19]. In this study, we found that the CD4/CD8 ratio rapidly and significantly increased to 0.48, 0.59, and 0.71 within the first 6 months of ART and reached 0.71, 0.83, and 0.90 after 5 years of ART in the patients with baseline CD4 counts of 200–349, 350–499, and ≥500 cells/µL, respectively. While the ratio gradually increased to 0.13 and 0.29 within the first 6 months of ART and reached 0.59 and 0.65 after 12 years of ART in the patients with baseline CD4 counts <50 and 50–199 cells/µL, respectively. In

Figure 3. The cumulative probability of restoration of CD4 count and CD4/CD8 ratio in HIV-1-infected patients after ART initiation. Analyses of the cumulative probability of CD4 counts reaching above 200 (A), 350 (B), and 500 cells/µL (C). The cumulative probability of CD4/CD8 ratio reaching above 0.4 (D) and 0.8 (E).
general, not all ART patients achieved a CD4/CD8 ratio \( \geq 1.0 \) even at the longest follow-up duration of 12 years (Figure 2(C)).

**The cumulative probability of immune restoration and its associated factors in HIV-1 patients on ART**

In this study, we found that 90% of all subjects with baseline CD4 counts \(< 50 \text{ cells/\( \mu \)L} \) achieved CD4 counts \( \geq 200 \text{ cells/\( \mu \)L} \) at 6 years after ART (Figure 3(A)). Around 90% of all subjects with baseline CD4 counts \(< 50 \) and 50–199 cells/\( \mu \)L achieved CD4 counts \( \geq 350 \text{ cells/\( \mu \)L} \) at the end of 12 years of ART (Figure 3(B)). While subjects with baseline CD4 counts \(< 50 \), 50–199, 200–349, and 350–499 cells/\( \mu \)L achieved CD4 counts \( \geq 500 \text{ cells/\( \mu \)L} \) at probabilities of 1.97, 7.84, 62.85, and 71.07%, respectively, at 12 months after ART. The cumulative probability was 63.68, 76.64, and 94.5% in patients with baseline CD4 counts \(< 50 \), 50–199, 200–349 cells/\( \mu \)L, respectively, after 10 years of ART. At the longest 12-year follow-up duration, only 73.19 and 84.48% of the surviving subjects with baseline CD4 counts \(< 50 \) and 50–199 cells/\( \mu \)L, respectively, achieved CD4 counts \( \geq 500 \text{ cells/\( \mu \)L} \). Patients with baseline CD4 counts \( \geq 350 \text{ cells/\( \mu \)L} \) could more easily reach CD4 counts \( \geq 500 \text{ cells/\( \mu \)L} \) within 6 months of ART (Figure 3(C)). In addition, we also calculated the time taken by 50 or 80% (probability) of patients with different baseline CD4 counts to achieve different CD4 recovery counts (e.g. \( \geq 200 \), \( \geq 350 \), and \( \geq 500 \text{ cells/\( \mu \)L} \)), which provides useful data for physicians (Appendix 3). Considering the restoration of CD4/CD8 ratio, we found that the higher the baseline CD4 counts, the easier it was to achieve CD4/CD8 ratios \( \geq 0.4 \) (Figure 3(D)) and \( \geq 0.8 \) (Figure 3(E)).

In the multivariate model, females, younger age, men who have sex with men (MSM), higher baseline CD4 counts and CD8 counts, hepatitis B surface antigen (HBsAg) negative, and protease inhibitor (PI)-based regimens were strongly associated with CD4 counts \( \geq 500 \text{ cells/\( \mu \)L} \) (Appendix 4). While lower CD8 counts were associated with CD4/CD8 ratios \( \geq 0.4 \) and \( \geq 0.8 \) (Appendix 5, 6).

**The cumulative probabilities of death and its associated factors in HIV-1-Infected patients on ART**

In this dynamic cohort, 3,134 deaths from 91,805 patients were identified for mortality analysis. In general, the mortality rates during the first year of ART among patients with baseline CD4 counts \(< 350 \text{ cells/\( \mu \)L} \) significantly decreased through the changes of ART-eligible policies (Figure 4(A)). The cumulative probability of death among different groups of baseline CD4 counts was significantly different after initiation of ART. At the end of the first year, the probabilities of death were 5.53, 2.08, 0.59, 0.27, and 0.23% in patients with baseline CD4 counts \(< 50 \), 50–199, 200–349, 350–499, and \( \geq 500 \text{ cells/\( \mu \)L} \), respectively. With the increase of ART duration, the corresponding death probabilities persistently increased to 11.9, 8.99, 5.38, 3.98, and 1.81%, respectively, after 10 years of ART (Figure 4(B)). Note that 26 patients with baseline CD4 \( > 500 \text{ cells/\( \mu \)L} \) that underwent ART were followed up for 10 years. The cumulative mortality was much higher in patients with baseline CD8 counts \(< 500 \text{ cells/\( \mu \)L} \) than in patients with baseline CD8 counts of 500–1000 cells/\( \mu \)L (\( p < 0.001 \)) and \( \geq 1000 \text{ cells/\( \mu \)L} \) (\( p < 0.001 \)) (Figure 4(C)). In addition, at each follow-up period, the highest probabilities of death were observed in patients with baseline CD4/CD8 ratio \( < 0.1 \), followed by patients with baseline CD4/CD8 ratio of 0.1–0.19. Patients with CD4/CD8 ratio of 0.2–0.39 had similar cumulative probabilities of death as patients with CD4/CD8 ratio \( \geq 0.4 \) (\( p = 0.09 \); Figure 4(D)).

With the multivariable Cox proportional hazard model, we found that male, older age, lower baseline hemoglobin and CD4 counts and CD8 counts, advanced WHO clinical stage, HBsAg positive, positive of antibody to hepatitis C virus, tuberculosis, and PI-based regimen were associated with a high risk of mortality (Figure 5).

**Binary-indicator immune restoration and death probabilities**

A total of 1,617 deaths from the immune analysis group were selected for comparative analysis of the probabilities of death. Firstly, we found that patients achieving CD4 counts \( \geq 500 \text{ cells/\( \mu \)L} \) among different CD4 count restoration strata (\( p < 0.0001 \) for pairwise comparison; Figure 6(A)) or CD4/CD8 ratio \( \geq 0.8 \) among different CD4/CD8 ratio restoration strata (\( p = 0.501 \) for comparison of CD4/CD8 ratio 0.8–0.99 and \( \geq 1.0 \), while \( p < 0.05 \) for comparison of CD4/CD8 ratio 0.8–0.99 vs. each group with CD4/CD8 ratio \( < 0.8 \); Figure 6(B)) had the lowest probability of death. Next, we found that patients achieving binary-indicator immune restoration had lower probabilities of death than patients achieving CD4 counts \( \geq 500 \text{ cells/\( \mu \)L} \) (2.77% vs 3.50%, \( p = 0.020 \); Figure 6(C)), or CD4/CD8 ratio \( \geq 0.8 \) (2.77% vs 4.28%, \( p < 0.001 \); Figure 6(C)) after 12 years of ART. The calculated threshold of CD8 count was approximately 600 cells/\( \mu \)L when the CD4 count was 500 cells/\( \mu \)L and the CD4/CD8 ratio was 0.8. We further compared the probabilities of death between patients achieving CD4 counts \( \geq 500 \text{ cells/\( \mu \)L} \) and \( \geq 500 \text{ cells/\( \mu \)L} \) with lower CD4/CD8 ratios \( < 0.8 \) (Figure 6(D)), or CD4/CD8 ratio \( < 0.8 \) (Figure 6(E)).
µL and CD4/CD8 ratio ≥0.8, with CD8 counts <600 cells/µL or CD8 counts ≥600 cells/µL, and found no significant difference between the two groups (p > 0.05; Figure 6(D)). Finally, we found that patients achieving binary-indicator immune restoration had lower probability of death than not achieving this binary-indicator goal (2.77% vs 8.93%, p < 0.001; Figure 6(E)).

Based on the above comparisons of probability of death, we proposed a new assessment system for immune restoration, which was defined as the simultaneous achievement of CD4 counts ≥500 cells/µL and CD4/CD8 ratio ≥0.8. Finally, 18,819 of 81,178 patients achieved the binary-indicator based therapy goal; the cumulative probability of achieving the new therapy goal in patients with baseline CD4 counts <50, 50–199, 200–349, 350–499, and ≥500 cells/µL was 31.29, 49.00, 74.38, 89.06, and 90.60%, respectively, after 12 years of ART (Figure 6(F)), which was lower than that of achieving CD4 counts ≥500 cells/µL alone at the paralleled follow-up points. Note that 22 patients with baseline CD4 counts 350–499 cells/µL and 5 patients with baseline CD4 counts ≥500 cells/µL were followed up for 12 years, respectively. At last, except for one patient in group of baseline CD4 counts 350–499 cells/µL, all patients in both of those two groups had achieved the binary-indicator based therapy goal before 12th year of study period.

**Discussion**

In this study, we comprehensively analyzed the dynamics of cumulative immune restoration, overall mortality, and associated risk factors among 91,805 patients who underwent 12 years of ART in China. Our findings showed that: (1) long-term ART resulted in different degrees of immune restoration, reflected by a continuous increase of CD4 counts and CD4/CD8 ratio, as well as partial restoration of CD8 counts, (2) through expanding ART eligibility criteria and optimizing ART regimen for PLWH, the mortality rate could be significantly reduced, and (3) compared with a single immune parameter-based system, a binary indicator-based immune assessment system (CD4 counts ≥500 cells/µL and CD4/CD8 ratio ≥0.8) could more accurately evaluate the extent of immune restoration and predict the probabilities of death in the era of “treat all.”

We found that patients with baseline CD4 counts <200 cells/µL, especially with baseline CD4 counts <50 cells/µL, were unable to reach normalized CD4 counts even after a decade of ART compared to
those with CD4 counts $\geq 350$ cells/$\mu$L. Poor CD4 counts restoration may possibly be associated with increased intrinsic CD4 loss, pathological lesions in the lymphoid tissues, and thymic and lymphoid differentiation dysfunction, particularly at the late stages of disease, even in patients with persistent viral suppression after ART [20–24]. Further, we also found that the CD8 counts remained above the normal level in HIV-1 patients receiving long-term ART, regardless of their CD4 counts. Currently, available evidence suggests that ART can only induce partial normalization of the frequency, activation, and diversity of global CD8 T cells [25]. For patients with undetectable HIV RNA, overactivation and expansion of CD8 T cells, as well as systemic inflammatory lesions could be reduced, but not eliminated due to the presence of HIV-1 antigens and gut microbiota perturbation/translocation [26]. Similar to CD4 counts, we found that the CD4/CD8 ratio showed an increasing trajectory after ART initiation; however, majority of the patients were unable to achieve a ratio of 0.8 due to the high levels of CD8 counts and insufficient CD4 counts restoration. It has been reported that there is a negative correlation between CD4/CD8 ratio and T-cell senescence and activation/exhaustion despite peripheral CD4 restoration [27]. Furthermore, several studies have also shown that incomplete recovery of CD4 counts, CD8 counts, or CD4/CD8 ratio is independently associated with a higher risk of severe outcomes, such as AIDS- or non-AIDS-related events and death [6,7,28–33]. In summary, CD4 counts, CD8 counts, and CD4/CD8 ratio reflect the immune status and predict different outcomes.

Previously, the restoration of CD4 cell counts was used as the major indicator of successful immune restoration [32]. In the era of "treat all," some patients with HIV start their ART at CD4 counts $\geq 500$ cells/$\mu$L. Hence, multiple immune parameters are required to assess immune restoration in such patients. In 2017, Lee and colleagues [34] proposed achieving CD4 $\geq 500$ cells/$\mu$L and CD4:CD8 ratio $\geq 0.8$ concurrently as an optimal immune outcome to investigate related

| Sex        | MR/10000 PY | AHR (95% CI) | P-value |
|------------|-------------|--------------|---------|
| Female     | 1           | 1.32(1.20-1.44) | <0.0001|
| Male       | 96          | 1            |         |
| Age, years |             |              |         |
| 15-29      | 25          | 1            |         |
| 30-44      | 111         | 1            |         |
| 45-59      | 142         | 1            |         |
| $\geq 60$  | 403         | 1            |         |

**Table 1.** Cox proportional hazard regression analysis to identify factors associated with mortality. For regression analysis, the mortality rate per 10,000 person-years was adjusted for age, sex, infection route, WHO clinical stages, HBsAg positive, Anti-HCV positive, tuberculosis, baseline hemoglobin, baseline CD4 count, baseline CD8 count, and ART regimen. The rate difference was calculated as the adjusted mortality rate of patients on ART. The boxes represent hazard ratios, the horizontal lines represent 95% CI. MSM, men who have sex with men; HC, heterosexual contact; IDU, injecting drug users; BT, blood transfusion; Hb, hemoglobin; ART, antiretroviral therapy; MR, mortality rate; AHR, adjusted hazard ratio; HBsAg, hepatitis B surface antigen; Anti-HCV, antibody to hepatitis C virus; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Figure 5. Cox proportional hazard regression analysis to identify factors associated with mortality.

| Age, years | MR/10000 PY | AHR (95% CI) | P-value |
|------------|-------------|--------------|---------|
| 15-29      | 25          | 1            |         |
| 30-44      | 111         | 1            |         |
| 45-59      | 142         | 1            |         |
| $\geq 60$  | 403         | 1            |         |

...
factors. However, their study did not provide evidence for identifying cutoff values of CD4 count and CD4: CD8 ratio, and did not investigate the association between achieving binary-indicator immune recovery and prognosis. In this study, for the first time, we proposed the best cutoff value of CD4 counts ($\geq 500$ cells/$\mu$L) and CD4/CD8 ratio ($\geq 0.8$) in this binary-indicator assessment, based on comparison of mortality in the setting of various immune restoration. We found that the cumulative probability of binary-indicator immune restoration in patients was lower than that of CD4 $\geq 500$ cells/$\mu$L alone. Furthermore, we found that patients achieving both CD4 counts $\geq 500$ cells/$\mu$L and CD4/CD8 ratio $\geq 0.8$ had lower probabilities of death than patients achieving CD4 counts $\geq 500$ cells/$\mu$L, or CD4/CD8 ratio $\geq 0.8$, or not achieving this binary indicator-based goal after 12 years of ART. Several studies confirmed that achieving CD4 counts $\geq 500$ cells/$\mu$L was associated with a lower mortality [29,35]. Although few studies investigated the association between CD4/CD8 ratio restoration $\geq 0.8$ and mortality, Demontès M, et al. [36] reported multimorbidity was associated with CD4/CD8 ratio < 0.8, and Marianna M, et al. [37] found CD4/CD8 ratio <

Figure 6. Comparison of cumulative probability of death among HIV-1-infected patients with different immune restoration status. Comparison of the cumulative probability of death between HIV-1-infected patients achieving CD4 counts $\geq 350$, 350–499, and $\geq 500$ cells/$\mu$L (A), CD4/CD8 ratio $<0.4$, 0.4–0.59, 0.6–0.79, 0.8–0.99, and $\geq 1.0$ (B), CD4 counts $\geq 500$ cells/$\mu$L and CD4/CD8 ratio $\geq 0.8$, and binary indicator-based immune restoration (simultaneously achieving CD4 counts $\geq 500$ cells/$\mu$L and CD4/CD8 ratio $\geq 0.8$) (C), binary indicator-based immune restoration with CD8 counts $\geq 600$ and <600 cells/$\mu$L (D), binary indicator-based immune restoration and incomplete immune restoration (E). The cumulative probability of binary indicator-based immune restoration among patients with different baseline CD4 counts (F).
0.8 could be used as a predictor for cardiovascular diseases. This new system could have several important implications in clinical practice: (1) it could guide physicians, healthcare providers, and social workers to accurately assess the immune status upon ART, and retarget those patients who were considered to have achieved immune restoration based on normalized CD4 counts alone, (2) in the era of “treat all”, using CD4 cell counts as the only immune evaluation parameter may lead to the overestimation of successful immune restoration and neglect of the risk of death in patients with HIV, (3) the high probability of incomplete immune reconstitution after long-term treatment implies that only ART might not be sufficient to achieve complete immune restoration.

Globally, the annual number of deaths from AIDS-related illness among PLWH has fallen from a peak of 1.7 million in 2004 (initiating ART) to 770,000 in 2018, as reported by UNAIDS. Based on the NFATP database, we also observed a significant decrease in mortality rates within the first year of ART, based on each ART-eligible policy for PLWH with baseline CD4 counts <350 cells/µL, especially for PLWH with baseline CD4 counts <200 cells/µL. This observation could be attributed to the in-time change of ART-eligible policy, the increasing coverage of care, the introduction of new treatment drugs, and the optimization of treatment regimen in China.

This study has certain limitations. First, clinical data, including HIV RNA, clinical symptoms, opportunistic infections, and cause of death were not mandatory fields for the NFATP database. This may partially influence the analysis of factors associated with immune restoration and mortality. Second, due to the low quality of data, such as high proportion of missing variables, frequent loss of follow-up in some hospitals, and so on, this study enrolled patients in 17 tertiary hospitals. The study participants accounted for approximately one-tenth of all PLWH receiving ART and male participants accounted for over than 80%, which well-represented the regional and gender distribution of HIV-1 patients in China. However, there is still an inevitable selection bias in our study. Third, in this real-world study, certain unmeasured confounders and censored data may have influenced the results. Fourth, the eligibility of free ART for HIV-1 patients in China was CD4 < 500 cells/µL since 2014, and changed to all infected patients regardless of CD4 count since 2016, which can explain why only small number of patients with baseline CD4 ≥ 350 cells/µL underwent 10 years of ART treatment in our cohort.

In conclusion, the findings of our study indicate that all HIV-1 patients on long-term ART achieve different degrees of immune restoration. Here, we proposed that a new binary indicator-based immune assessment system (CD4 counts ≥500 cells/µL and CD4/CD8 ratio ≥0.8) could more accurately assess the function and status of the immune system and predict the probability of death after long-term ART in the era of “treat all.” However, further validation is needed to confirm its applicability.

Acknowledgement
We thank the staff of the local counties’ Centers for Disease Control for their assistance in obtaining, verifying, and cleaning data used in this study.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was supported by the National Science and Technology Major Project of Infectious Disease (2017ZX10202102-004-002 and 2018ZX10302104-002) and the National Natural Science Foundation of China (81721002).

Author Contributions
F-S. Wang, GFG, M. Han, and L. Wang conceived and designed the study. J. Liu, L. Wang, Y. Hou, Y. Wu, D. Zhao, Y. Zhao, and Y. Ma collected the data. J. Liu, L. Wang, Y. Hou, and D. Zhang analyzed the data. F-S. Wang, J. Liu, L. Wang, Y. Hou, Y. Ma, F. Zhang, Z. Wu, and D. Zhang interpreted the data. J. Zhang, Z. Liu, R. Xu, and L. Huang suggested additional analyses. F-S. Wang, J. Liu, L. Wang, Y. Hou, and L. Jin designed the figures. F-S. Wang, J. Liu, L. Wang, Y. Hou wrote the first draft of the manuscript. All authors reviewed, revised, and approved the final manuscript.

ORCID
George F. Gao http://orcid.org/0000-0002-3869-615X

References
[1] Ghosn J, Taiwo B, Seedat S, et al. HIV. Lancet. 2018 Aug 25;392(10148):685–697. doi:10.1016/s0140-6736(18)31311-4.
[2] Lundgren JD, Babiker AG, Gorden F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. doi:10.1056/NEJMoa1506816.
[3] Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis. 2007;195(3):425–431. doi:10.1086/510536.
[4] Nsanzimana S, Remera E, Kanters S, et al. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in
HIV-positive adult patients in Rwanda: a nationwide cohort study. Lancet HIV. 2015;2(9):e376–e384. doi:10.1016/s2352-3018(15)00112-5.

[5] Trickey A, May MT, Schommers P, et al. CD4/CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the antiretroviral therapy cohort Collaboration (ART-CC). Clin Infect Dis. 2021;65(6):959–966. doi:10.1093/cid/cix466.

[6] Mussini C, Lorenzini P, Cozzi-Leprai A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar;2(3):e98–106. doi:10.1016/s2352-3018(15)00060-5.

[7] Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078. doi:10.1371/journal.ppat.1004078.

[8] Ma Y, Dou Z, Guo W, et al. The Human immunodeficiency virus care Continuum in China: 1998-2015. Clin Infec Dis. 2018 Mar;56(6):833–839. doi:10.1093/cid/cix911.

[9] Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003–2009. J Acquir Immune Defic Syndr. 2013;63(5):e150–e157. doi:10.1097/QAI.0b013e3282f9d8d2.

[10] Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the Chinese national free antiretroviral treatment program. Ann Intern Med. 2009;151(4):241–251. doi:10.7326/0003-4819-151-4-20090818-00006.

[11] Chen M, Dou Z, Wang L, et al. Gender differences in outcomes of antiretroviral treatment among HIV-infected patients in China: a retrospective cohort study, 2010–2015. J Acquir Immune Defic Syndr. 2021;76(3):281–288. doi:10.1097/qai.0000000000001500.

[12] Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008;47(6):825–833. doi:10.1086/590945.

[13] Ma Y, Zhang F, Zhao Y, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol. 2010;39(4):973–979. doi:10.1093/ije/dyp233.

[14] Chinese Center for Disease Control and Prevention. China free ART manual. Beijing: Ministry of Health; 2005.

[15] Qiu P, Sheng J. A two-stage procedure for comparing hazard rate functions. J R Stat Soc Series B Stat Methodol. 2008;70(1):191–208. doi:10.1111/j.1467-9868.2007.00622.x.

[16] Zhang F, Zhu H, Wu Y, et al. HIV, hepatitis B virus, and hepatitis C virus coinfection in patients in the China National free antiretroviral treatment Program, 2010–12: a retrospective observational cohort study. Lancet Infect Dis. 2014;14(11):1065–1072. doi:10.1016/s1473-3099(14)70946-6.

[17] Weimin J, Pan X, Kang L, et al. Comparison between values of CD4, CD8, CD4/CD8 among HIV infected and normal adults in Shanghai. China J AIDS/STD. 2002;8(2):71–73.

[18] Liu S, Liu W, Chen J. Analysis of T lymphocyte subsets in normal healthy Chinese adults in the Guangxi Zhuang Autonomous Region. China J AIDS(STD. 2004;6(10):413–415.

[19] Jian-Mei HE, Zou XB, Peng JY, et al. Normal reference values of peripheral blood CD3+, CD4+ and CD8+ T lymphocytes in healthy Miao ethnics in Hunan province. Chin J Infect Control. 2009;8(002):82–85.

[20] Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004 Sep 20;200(6):749–759. doi:10.1084/jem.20040874.

[21] Ferrando-Martinez S, De Pablo-Bernal RS, De Luna-Romero M, et al. Thymic function failure is associated with human immunodeficiency virus disease progression. Clin Infec Dis. 2017 May 1;64(9):1191–1197. doi:10.1093/cid/cix095.

[22] Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010 May 1;50(9):1300–1308. doi:10.1086/651689.

[23] Rb-Silva R, Nobrega C, Azevedo C, et al. Thymic function as a predictor of immune recovery in Chronically HIV-infected patients initiating antiretroviral therapy. Front Immunol. 2019;10:25. doi:10.3389/fimmu.2019.00025.

[24] Shenoy MK, Fadroz DW, Lin DL, et al. Gut microbiota in HIV–pneumonia patients is related to peripheral CD4 counts, lung microbiota, and in vitro macrophage dysfunction. Microbiome. 2019 Mar 11;7(1):37. doi:10.1186/s40168-019-0651-4.

[25] Warren JA, Clutton G, Goonetilleke N. Harnessing CD8 T cells under HIV antiretroviral therapy. Front Immunol. 2019;10:291. doi:10.3389/fimmu.2019.00291.

[26] Cao W, Mehrav J, Kaufmann D E, et al. Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J Int AIDS Soc. 2016;19(1):20697. doi:10.7448/ias.19.1.20697.

[27] Sainz T, Serrano-Villar S, Diaz L, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS. 2013;27(9):1513–1516. doi:10.1097/QAD.0b013e32835fa72.

[28] Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014 May;58(9):1312–1321. doi:10.1093/cid/ciu308.

[29] Young J, Psychogius M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9(3):e1001194. doi:10.1371/journal.pmed.1001194.

[30] Roul H, Mary-Krause M, Ghosn J, et al. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. AIDS. 2018 Nov 13;32(17):2605–2614. doi:10.1097/QAD.0000000000002010.

[31] Tanuma J, Matsumoto S, Haneuse S, et al. Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected
adult cohort in Hanoi, Vietnam. J Int AIDS Soc 2017;20(4). doi:10.1002/jia2.25030.

[32] Okulicz JF, Le TD, Agan BK, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med. 2015 Jan;175(1):88–99. doi:10.1001/jamainternmed.2014.4010.

[33] Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. Br Med J. 2009;338:a3172. doi:10.1136/bmj.a3172.

[34] Lee SS, Wong NS, Wong BCK, et al. Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: an observational cohort study. BMJ Open. 2017;7(9):e016886. doi:10.1136/bmjopen-2017-016886.

[35] Gabillard D, Lewden C, Ndoye I, et al. Mortality, AIDS-morbidity and loss to follow-up by current CD4 cell count among HIV-1 infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr. 2013;62(5):555. doi:10.1097/QAI.0b013e318221821.

[36] Demontès M, Allavena C, Jovelín T, et al. Multimorbidity in elderly subjects according to the year of diagnosis of HIV-infection-A Cross-Sectional DAT AIDS cohort study. Clin Infect Dis. 2019. doi:10.1093/cid/ciz1171.

[37] Menozzi M, Zona S, Santoro A, et al. CD4/CD8 ratio is not predictive of multi-morbidity prevalence in HIV-infected patients but identify patients with higher CVD risk. J Int AIDS Soc. 2014;17(4 Suppl 3):19709. doi:10.7448/IAS.17.4.19709.